Final NICE no for Shire’s pancreatic cancer drug

28th March 2017 Uncategorised 0

Pancreatic cancer patients will not be able to get routine access to Shire’s Onivyde on the National Health Service following a final rejection from cost regulators

More: Final NICE no for Shire’s pancreatic cancer drug
Source: News